Cat. # | Size | Qty. | Price |
---|---|---|---|
60125T | 1 Kit (6 x 20 microliters) |
|
Product Includes | Quantity | Applications | Reactivity | MW(kDa) | Isotype |
---|---|---|---|---|---|
RNase L (D4B4J) Rabbit mAb 27281 | 20 µl |
|
H M | 80 | Rabbit IgG |
OAS1 (D1W3A) Rabbit mAb 14498 | 20 µl |
|
H | 40, 44 | Rabbit IgG |
OAS2 (E2G4K) Rabbit mAb 24344 | 20 µl |
|
H | 70 | Rabbit IgG |
OAS3 (E4X7Z) Rabbit mAb 74906 | 20 µl |
|
H | 120 | Rabbit IgG |
OASL (E7W1R) Rabbit mAb 36845 | 20 µl |
|
H | 52 | Rabbit IgG |
PDE12 (E2V7J) Rabbit mAb 88499 | 20 µl |
|
H M | 75, 70 | Rabbit IgG |
Anti-rabbit IgG, HRP-linked Antibody 7074 | 100 µl |
|
Rab | Goat |
Product Information
The 2'-5'-oligoadenylate synthetase (OAS)/RNase L pathway is a component of the antiviral innate immune system. The OAS family of proteins includes OAS1, OAS2, OAS3, and OASL in humans, all of which are induced in response to type 1 interferons (1-3). When activated by cytosolic double-stranded RNA, OAS1-3 generate 2’-5’-linked oligoadenylates that bind to and activate the ribonuclease, RNase L. Activated RNase L is poised to degrade viral and cellular RNA as part of the antiviral innate immune response (4). Unlike OAS1-3, OASL lacks intrinsic enzymatic activity, and research studies have suggested that OASL participates in the antiviral immune response independently of the canonical OAS/RNase L signaling pathway (5,6). Negative regulation of the OAS/RNase L pathway is governed, in part, by the PDE12 phosphodiesterase that degrades 2'-5'-oligoadenylates (7).
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.